On Thursday, August 13, Myriad Genetics MYGN will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
Earnings and Revenue
Analysts are expecting Myriad Genetics to report a loss of $0.47 per share. Revenue will likely be around $93.85 million, according to the consensus estimate. In the same quarter last year, Myriad Genetics reported EPS of $0.41 on revenue of $215.40 million. The Wall Street estimate would represent a 214.63% decline in the company's earnings. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
| Quarter | Q3 2020 | Q2 2020 | Q1 2019 | Q4 2019 |
|---|---|---|---|---|
| EPS Estimate | 0.02 | 0.31 | 0.32 | 0.47 |
| EPS Actual | -0.08 | 0.23 | 0.08 | 0.41 |
| Revenue Estimate | 167.19 M | 209.81 M | 202.10 M | 221.04 M |
| Revenue Actual | 164.00 M | 195.10 M | 186.30 M | 215.40 M |
Stock Performance
Over the past 52-week period, shares of Myriad Genetics have declined 46.34%.
Bearing these returns in mind, shareholders will probably be dissatisfied going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Myriad Genetics is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/6w3d9td9
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
